LFB Biomanufacturing
Les Ulis, France
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: LFB Biomanufacturing
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Les Ulis, France
- Modalities
- Monoclonal Antibody, Recombinant Protein, Bispecifics, Fc-fusions, Biologics
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About LFB Biomanufacturing
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, Bispecifics, Fc-fusions, Biologics
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (5 modalities)
Recent News 9 articles
Sartorius strengthens collaboration with LFB Biomanufacturing - BioSpectrum Asia
Made Scientific and Sentinel BioTherapeutics join forces to advance cell-therapy program - BioProcess International
Sartorius, LFB expand partnership for cell-line development - BioProcess International
Sartorius, LFB Biomanufacturing Expand Collaboration - Contract Pharma
Transforming Biomanufacturing with AI and Quantum Technologies - BioProcess International
France's LFB Biomanufacturing launches €20M cell production plant expansion - Fierce Pharma
eBook: Allogeneic Cell Therapy — From Clinical Concept to Viable Product - BioProcess International
ARPA-H awards BioCurie $9.3m to support AI-driven gene therapy platform - BioProcess International
Rentschler: A World-Class Biopharmaceutical CDMO - BioProcess International
Frequently Asked Questions About LFB Biomanufacturing
What is LFB Biomanufacturing's CDMO Signal Score?
LFB Biomanufacturing has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating LFB Biomanufacturing for a manufacturing program?
Use the free AI matchmaker to compare LFB Biomanufacturing against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
Biologics / mAb Programs — Host Cell Protein (HCP) & Impurity-Driven Failures
N/A — Industry-Wide Pattern
Monoclonal Antibody, Recombinant Protein, Biologics
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
Rentschler Biopharma
Laupheim, Germany
Signal Score: 79.9
Monoclonal Antibody, Recombinant Protein